

NOV 06 2003

OFFICIAL

I hereby certify that this correspondence is being
facsimile transmitted to the United States Patent
and Trademark Office on the date shown below:

November 6, 2003David Saliwanchik

David R. Saliwanchik, Patent Attorney

ELECTION UNDER 35 USC § 121

Examining Group 1651

Patent Application

Docket No. GJE-68

Serial No. 09/856,944

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Vera Afremova
Art Unit : 1651
Applicants : John Ernest Hart
Serial No. : 09/856,944
Conf. No. : 6466
Filed : May 30, 2001
For : Isolated Material Having An Anti-organotrophic Effect

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

ELECTION UNDER 35 USC §121

Sir:

In response to the written Restriction Requirement dated October 6, 2003, the Applicant hereby elects, with traverse, to prosecute the Group I claims, i.e. claims 1, 3-6, 8 and 11-14, drawn to a material derived from ovarian venous blood and having molecular weight within 10-30 kDa and to a pharmaceutical composition with the material.

The applicant respectfully traverses the Restriction Requirement as being legally incorrect and particularly inappropriate under the circumstances. First, in the original application, from which this Request for Continued Examination was filed, the product claims and the method claims were examined. Please note that, if the search and examination of an entire application can be made without serious burden, the Examiner must examine it on the merits, even though it includes claims

to independent or distinct inventions (MPEP § 803 *et seq.*). It is unclear why the examination of all of the claims would now be a serious burden when it was not in the original case.

Furthermore, the applicants respectfully submit that, contrary to what is stated in the Restriction Requirement, there is a unifying technical feature to the claims that have been presented for examination. Please note that in characterizing the technical features of the composition the Restriction Requirement omits perhaps the most important technical features- that the material is inducible by clomiphene and has the ability to reduce organ mass of body organs including non-gonadol organs.

As has been described in detail in the original application, and now further explained in Dr. Hart's declaration, the currently-claimed composition is simply not the same as that which is disclosed in the prior art.

Accordingly, the applicant respectfully requests examination at this time of all of the pending claims. Alternatively, if this request is denied, the applicant respectfully requests re-joinder of the method claims upon an indication of allowability of the composition claims.

The Commissioner is hereby authorized to charge any fees under 37 CFR 1.16 or 1.17 as required by this paper to Deposit Account 19-0065.

The Applicants invite the Examiner to call the undersigned if clarification is needed on any aspect of this amendment.

Respectfully submitted,



David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.: 352-375-8100

Address : 2421 N.W. 41st Street
Suite A-1
Gainesville, FL 32606

DRS/ba

FACSIMILE COVER SHEET

SALIWANCHIK, LLOYD & SALIWANCHIK

A Professional Association
2421 N.W. 41st Street
Suite A-1
Gainesville, FL 32606

Telephone (352) 375-8100
Facsimile (352) 372-5800

**RECEIVED
CENTRAL FAX CENTER**

NOV 06 2003

OFFICIAL

TO: Examiner Vera Afremova

FROM: David R. Saliwanchik

COMPANY: U.S. Patent Office
Art Unit 1651

DATE: November 6, 2003

FAX NO.: (703) 872-9306

**NO. OF PAGES
(INCLUDING COVER SHEET):** 3

SUBJECT/MESSAGE:

Re: Serial No. 09/856,944; filed May 30, 2001

- 1) Election Under 35 U.S.C. §121 (2 pages)

**THIS IS AN OFFICIAL DOCUMENT!
PLEASE DELIVER TO EXAMINER AFREMOVA IMMEDIATELY**

The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named below. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.

*If you do not receive all pages or if any transmission is not legible,
call the sender at (352) 375-8100.*

H:\DOC\FAXCOVER\PTO\AFREMOVA-1651.DOC/RES/la